Accessing this content is a benefit of AAGL Membership
To continue, please log into your AAGL membership account:

AAGL Username



Click on the poster above to navigate to the next slide

Call for Comments due 4/27/2020: FDA Draft Guidance Document on Power Morcellators

The following statement was authored by Dr. Jubilee Brown, President of the AAGL, and summarizes the AAGL’s Endorsement of the FDA Draft Guidance Document on Product Labeling for Laparoscopic Power Morcellators.  This statement was approved by the AAGL Board of Directors.

The AAGL endorses the Draft Guidance Document released today by the FDA on power morcellation. The document can be found here and includes product labeling for laparoscopic power morcellators and provides draft guidance for industry and FDA Staff. This guidance document includes recommended labeling on laparoscopic power morcellators to inform physicians that these devices are: contraindicated in gynecologic surgery in which the tissue to be morcellated is known or suspected to contain malignancy; are contraindicated for removal of uterine tissue containing suspected fibroids in patients who are post-menopausal or over 50 years of age, or candidates for en bloc tissue removal through the vagina or via a mini-laparotomy incision; that the risk of occult cancer increases with age, particularly over age 50; that uncontained power morcellation has been associated with the spread of benign uterine tissue; and that these devices should only be used with a containment system compatible with the laparoscopic power morcellator.

The specification of age-related risk is consistent with scientific data and reflects clinical experience, allowing power morcellation in low risk patients when performed with a containment system compatible with the laparoscopic power morcellator. Utility of a contained tissue extraction system in a low risk population appears to mitigate the risk of poor outcomes that may be associated with uncontained power morcellation.

This updated guidance document and the associated labeling allows physicians and their patients to make informed decisions based on the most current scientific information and provides expanded safe options for minimally invasive gynecologic surgery in appropriate, low-risk, screened patients after informed consent.

The AAGL encourages its members to contribute their opinions by submitting electronic comments to the FDA’s Federal register here during the 60-day window. The FDA will consider these responses as they finalize this guidance document.

Jubilee Brown, MD
AAGL President
Issued 2/25/2020

Review the Document

Filed under "News, Press Releases".

So, for a woman's part, if you want to see stars having arab sex on a tube site in HD, do not be surprised, just visit to xnxx website. Most mature sex women here have come to realize that the path to happiness and material wealth does not come without some form of sexual enjoyment or sex. Many young Arab girls in their thirties and up have become sex models at the hands of some well intentioned older men. There is nothing wrong with that either. Read more arab sex stories on
AAGL – Elevating Gynecologic Surgery
6757 Katella Avenue | Cypress, CA 90630
(800) 554-2245 | (714) 503-6200
By using, you agree that you've read and accept our Privacy Policy.
css.php Medical Device Marketing